Metavia Inc stock is traded at $1.09, with a volume of 1,083,202. It is down -18.66% in the last 24 hours and down -26.35% over the past month. MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
Previous Close:
$1.34
Open:
$1.40
24h Volume:
1,083,202
Relative Volume:
5.69
Market Cap:
$7.18M
Revenue:
-
Net Income/Loss:
-$13.13M
P/E Ratio:
-
EPS:
-$6.02
Net Cash Flow:
-$15.15M
1W Performance:
-2.68%
1M Performance:
-26.35%
6M Performance:
-22.14%
1Y Performance:
-88.34%
1-Day Range:
$0.00$0.00
1-Week Range:
$1.02$1.45
52-Week Range:
$0.9661$14.85
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia IncSector
HealthcareIndustry
BiotechnologyPhone
(857) 702-9600Address
545 CONCORD AVENUE, CAMBRIDGE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS